Literature DB >> 29846244

Markers of the HIV-1 reservoir: facts and controversies.

Timothée Bruel1,2,3, Olivier Schwartz1,2,3.   

Abstract

PURPOSE OF REVIEW: The HIV-1 reservoir is composed of infected cells poised to replicate and spread the virus upon treatment interruption. It constitutes the main obstacle toward an HIV-1 cure. Whether marker(s) may allow the detection of cells that form the reservoir is an outstanding question. Here, we present and discuss recent advances and controversies in the identification and characterization of markers of the HIV-1 reservoir. RECENT
FINDINGS: Latently infected T cells that persist under successful therapy do not express viral antigens, making their identification challenging. HIV is not equally distributed across T cells subsets. For instance, central memory, Th17, and T follicular helper cells largely contribute to viral persistence. Recently, novel markers of the reservoir have been identified. Using various strategies, different teams have reported that surface molecules such as immune checkpoints inhibitors, CD30, or CD32a may be enriched in latently infected cells or in cells harboring viral RNA.
SUMMARY: Understanding the mechanisms underlying the presence of markers of HIV-1 infected cells will provide new insights into the formation and maintenance of the viral reservoir. These markers should also facilitate the detection of persistently infected cells in patients' samples and in animal models, and represent potential targets for elimination of these cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29846244     DOI: 10.1097/COH.0000000000000482

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  14 in total

1.  Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.

Authors:  Chia-Ching Wang; Cassandra Thanh; Erica A Gibson; Maya Ball-Burack; Louise E Hogan; Benjamin Descours; Norman Jones; Alexander B Carvidi; Sadie Munter; Sonia Bakkour; Michael P Busch; Jeffrey M Milush; Steven G Deeks; Timothy J Henrich
Journal:  Blood Adv       Date:  2018-12-11

2.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

Review 3.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Targeting HIV-1 proviral transcription.

Authors:  Alex Olson; Binita Basukala; Wilson W Wong; Andrew J Henderson
Journal:  Curr Opin Virol       Date:  2019-08-29       Impact factor: 7.121

Review 5.  The Contributions of Clinical Pharmacology to HIV Cure Research.

Authors:  Courtney V Fletcher; Shetty Ravi Dyavar; Arpan Acharya; Siddappa N Byrareddy
Journal:  Clin Pharmacol Ther       Date:  2021-04-18       Impact factor: 6.903

6.  Single-Cell Profiling of Latently SIV-Infected CD4+ T Cells Directly Ex Vivo to Reveal Host Factors Supporting Reservoir Persistence.

Authors:  Andrey Tokarev; Kawthar Machmach; Matthew Creegan; Dohoon Kim; Michael A Eller; Diane L Bolton
Journal:  Microbiol Spectr       Date:  2022-05-05

7.  CD161+ CD4+ T Cells Harbor Clonally Expanded Replication-Competent HIV-1 in Antiretroviral Therapy-Suppressed Individuals.

Authors:  Xiaomin Li; Zhaoli Liu; Qijuan Li; Ronglin Hu; Lu Zhao; Yanyan Yang; Jiacong Zhao; Zhuoqiong Huang; Hongbo Gao; Linghua Li; Weiping Cai; Kai Deng
Journal:  mBio       Date:  2019-10-08       Impact factor: 7.867

Review 8.  The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like.

Authors:  Gilles Darcis; Ben Berkhout; Alexander O Pasternak
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

Review 9.  Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure.

Authors:  Luisa Mori; Susana T Valente
Journal:  Viruses       Date:  2020-05-11       Impact factor: 5.048

Review 10.  Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.

Authors:  Jeffrey C Umotoy; Steven W de Taeye
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.